Canada markets closed

Synthetic Biologics, Inc. (SYN)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.2300+0.0167 (+7.83%)
At close: 04:00PM EDT
0.2300 0.00 (0.00%)
After hours: 07:41PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.2133
Open0.2035
Bid0.2155 x 1000
Ask0.2300 x 38800
Day's Range0.2001 - 0.2380
52 Week Range0.1800 - 0.5700
Volume1,540,673
Avg. Volume874,338
Market Cap36.441M
Beta (5Y Monthly)1.66
PE Ratio (TTM)N/A
EPS (TTM)-0.1200
Earnings DateAug 03, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.63
  • GlobeNewswire

    Synthetic Biologics Reports First Quarter 2022 Operational Highlights and Financial Results

    -Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed publication highlighting positive clinical data on VCN-01 and an upcoming oral presentation on VCN-11, a novel oncolytic adenovirus designed to evade neutralizing antibodies- - Reported positive safety data on SYN-020 intestinal alkaline phosphatase from the Phase 1 Multiple Ascending Dose clinical trial- -Formed Scientific Advisory Board and strengthened the leadership team

  • GlobeNewswire

    Synthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial

    -Orally administered SYN-020 observed to be well tolerated across all doses in healthy volunteers- ROCKVILLE, Md., May 10, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced positive safety data from its Phase 1, placebo-controlled, double-blind multiple ascending dose (MAD) clinical trial of SYN-020 intestinal alkaline phosphatase (IAP). The

  • GlobeNewswire

    Synthetic Biologics to Host Conference Call and Webcast to Discuss First Quarter 2022 Operational Highlights and Financial Results

    ROCKVILLE, Md., May 09, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Monday, May 16, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended March 31, 2022 and provide a corporate update. Individuals may participate in the live call via telephone by dialing (877) 451-6152 (d